INVL Private Equity Fund II, the largest private equity fund in the Baltics, managed by the Invalda INVL Group, together with the International Finance Corporation (IFC), a member of the World Bank Group, and Accession Capital Partners (ACP) have signed an agreement to invest in POLMED. POLMED is one of Poland\u2019s largest private providers of multi-profile medical services. The consortium will provide expansion capital to finance the acquisition of KN Group, a leading privately-owned oncology centre. Upon completion, this will mark one of the first two acquisitions by the INVL Private Equity Fund II.<\/p>\n
Founded in 1999, POLMED has grown into one of the Poland\u2019s leading private healthcare groups, generating revenues of more than EUR 100 million in 2024. The company operates across outpatient care, imaging diagnostics, home and stationary rehabilitation. With a network of 38 of its own facilities and 2,000 employees, it collaborates with over 4,000 medical partners across Poland, serving over 4 million patients annually and providing services to over 3,500 corporate clients.<\/p>\n
The add-on acquisition target, Radomskie Centrum Onkologii (RCO), Gamma Knife Centre and Radom Family Centre (RFC) (together \u2013 KN Group), was founded in 2011, and is a leading private oncology centre in Poland. It owns three facilities in Radom, and Warsaw, employing over 700 people and operating 150 beds, including 14 chemotherapy chairs. The target is run by world-class neurosurgeon prof. Miros\u0142aw Z\u0105bek and Dorota Z\u0105bek, who will both continue working for the company.<\/p>\n
Transaction is subject to merger approval from the Polish Office of Competition and Consumer Protection and other conditions precedent. INVL Private Equity Fund II, IFC and ACP, will each hold significant minority stakes in the combined entity, while POLMED\u2019s founder and president Rados\u0142aw Szubert together with co-founder and vice-president Romuald Magdo\u0144 will remain the majority shareholders and continue leading the company. A strong founder leadership, backed by the support and proven expertise of the investors, will accelerate POLMED\u2019s next growth phase.<\/p>\n
Rados\u0142aw Szubert, founder and president of POLMED, commented: \u201cThe connection with the Neurosurgery Clinics perfectly fits into the strategy of POLMED, which aims to increase the complexity of the Group’s services with the patient in mind and to ensure the best possible comfort during diagnostics and therapy. The inclusion of the oncology hospital and the Gamma Knife is part of the strategy implementation. Patients will be provided with an increased amount of services offered by the POLMED Group, which will translate into their comfort of treatment.\u201d<\/p>\n
On behalf of KN Group, vice president Dorota Z\u0105bek commented: \u201cBoth the hospital in Radom and Gamma Knife fulfil the tasks set by patients. We offer both diagnostics and comprehensive oncological treatment at the highest global level. By joining the POLMED Group, we benefit our patients by enhancing the availability of advanced oncological treatments.\u201d<\/p>\n
Luke Staniczek, Investments Lead in Poland at INVL Private Equity Fund II, noted: \u201cOur journey with InMedica proved that with the right support, a healthcare provider can grow into a national leader and deliver outstanding results for everyone \u2013 shareholders, patients and healthcare ecosystem as a whole. We are confident that POLMED, its founders and their team all have the same potential in Poland, and we look forward to supporting their growth and building our success story together.\u201d<\/p>\n
\u201eIFC is supporting POLMED\u2019S transformation into an integrated, digitally enabled healthcare platform,\u201d said Ary Na\u00efm, World Bank Group Country Manager for Poland. \u201cThis will help expand access to quality care and improve the availability of specialized services in line with the country\u2019s evolving healthcare needs\u201d.<\/p>\n
Piotr Sadowski, Partner at ACP, said: \u201cThe impressive growth of POLMED is a testament to the strength of the leadership team, which we look forward to working with. Our rich experience in the healthcare sector gleaned through investments including Medicales, Optimapharm, Amethyst and LUX MED mean we understand the importance of improving patient outcomes, and we are well placed to support the team to do this."<\/p>\n
INVL Private Equity Fund II was represented by Baker McKenzie (legal advisor). Advisors on the deal also included CIC Corporate Finance (M&A for POLMED), EY\/EY Parthenon (financial, tax and commercial due diligence), Norton Rose Fulbright Dyczkowski and Partners (legal for ACP (documentation and due diligence)), MJH Moskwa, Jarmul, Ha\u0142adyj i Partnerzy (legal for POLMED\/vendor due diligence), Hogan Lovells International (legal for IFC), Pekao Investment Banking (M&A for KN Group), Doma\u0144ski Zakrzewski Palinka (legal and tax for KN Group).<\/p>\n
About INVL Private Equity Fund II<\/strong><\/p>\n The INVL Private Equity Fund II, the largest private equity fund in the Baltics, which held its first closing in February 2025 at EUR 305 million aims to build a diversified portfolio by acquiring majority or significant minority stakes in high-growth companies with investment of EUR 10 million to EUR 60 million. The fund focuses on businesses with strong potential to grow and compete amid intensifying global competition, targeting opportunities in the Baltic countries, Poland, Romania and the broader Europe Union.<\/p>\n The fund is managed by INVL Asset Management, the leading Baltic alternative asset manager, which is a part of the Invalda INVL Group with over 30 years of experience. The group\u2019s companies manage EUR 2 billion in assets across various investment strategies, including private equity, forests and agricultural land, renewable energy, real estate, and private debt. Additionally, the group provides family office services in Lithuania, Latvia and Estonia, manages pension funds in Latvia and invests in global third-party funds.<\/p>\n About POLMED<\/strong><\/p>\n Founded in 1999, POLMED has grown into one of the Poland\u2019s leading private healthcare groups, generating revenues of more than EUR 100 million in 2024. The company operates across outpatient care, imaging diagnostics, home and stationary rehabilitation. With a network of 38 of its own facilities and 2,000 employees, it collaborates with over 4,000 medical partners across Poland, serving over 4 million patients annually and providing services to over 3,500 corporate clients.<\/p>\n About the International Finance Corporation (IFC)<\/strong><\/p>\n IFC \u2014 a member of the World Bank Group \u2014 is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2025, IFC committed a record $71.7 billion to private companies and financial institutions in developing countries, leveraging private sector solutions and mobilizing private capital to create a world free of poverty on a livable planet. For more information, visit www.ifc.org.<\/p>\n Accession Capital Partners (ACP)<\/strong><\/p>\n Accession Capital Partners (ACP) is investing from its fifth fund AMC V SCA SICAV-RAIF which closed at EUR 336 million in June 2024. ACP has been operating in Central Europe since 2000 through its offices in Vienna, Warsaw, Bucharest, Budapest and Prague. To date, the group has raised commitments of more than EUR 1.2 billion in five dedicated growth capital funds. The funds are backed by reputable institutional investors, including the European Investment Fund, the International Finance Corporation, the European Bank for Reconstruction and Development and a number of banks, family offices, funds of funds, pension funds and insurance companies from Europe, the US and Asia.<\/p>\n Important information<\/strong><\/p>\n This is marketing communication of an information nature, which is not and shall not be construed as an offer to purchase investment units of a collective investment undertaking, an investment recommendation, or investment research, as it is not designed to take into account the investment objectives, financial situation, or needs any individual investor.<\/p>\n When investing, the investors assume the risk associated with the investment. The value of investments can both rise and fall, and an investor may recover less than he\/she\/it has invested. Past investment results do not guarantee the same results or profitability in the future. Past performance is not a reliable indicator of future performance. Before making a decision to invest, potential investors should, on their own or with the help of investment advisers, assess the suitability of the investment for them along with the taxes and fees related to the investment, consider all the risks related to the investment, and carefully read the rules, prospectus and other documents of the respective collective investment undertaking.<\/p>\n Units of this collective investment undertaking, mentioned in this press release may only be distributed to informed investors as defined in the Law on Collective Investment Undertakings for Informed Investors of the Republic of Lithuania, as amended and supplemented from time to time, and may not be distributed and transferred to any other clients.<\/p>\n","protected":false},"excerpt":{"rendered":" INVL Private Equity Fund II, the largest private equity fund in the Baltics, managed by the Invalda INVL Group, together with the International Finance Corporation (IFC), a member of the World Bank Group, and Accession Capital Partners (ACP) have signed an agreement to invest in POLMED. POLMED is one of Poland\u2019s largest private providers of […]<\/p>\n","protected":false},"author":4,"featured_media":200360,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[316],"tags":[369],"class_list":["post-200362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-invl-private-equity-fund-ii","tag-private-equity"],"acf":[],"yoast_head":"\n